scholarly article | Q13442814 |
P50 | author | Paul Bowman | Q7149470 |
Stephen P Hunger | Q64215088 | ||
Mary V Relling | Q88331217 | ||
Edward J Bedrick | Q90478028 | ||
Huining Kang | Q90676267 | ||
Gregory Reaman | Q99568579 | ||
Cheryl L. Willman | Q110811050 | ||
Michael J Borowitz | Q117236346 | ||
Bruce M Camitta | Q117251690 | ||
Carla S Wilson | Q117271260 | ||
Walker Wharton | Q117271261 | ||
Charles G. Mullighan | Q37839132 | ||
Deepa Bhojwani | Q42324985 | ||
Jun J Yang | Q59146633 | ||
Richard C Harvey | Q59219178 | ||
Malcolm A Smith | Q62764622 | ||
P2093 | author name string | Maurice Murphy | |
Andrew J Carroll | |||
Meenakshi Devidas | |||
Susan R Atlas | |||
Xuefei Wang | |||
James R Downing | |||
William L Carroll | |||
I-Ming Chen | |||
Kevin K Dobbin | |||
Kerem Ar | |||
George S Davidson | |||
P2860 | cites work | Augmented Post-Induction Therapy for Children with High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial Therapy | Q64225643 |
Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study | Q73720147 | ||
Outlier sums for differential gene expression analysis | Q83348051 | ||
Cluster analysis and display of genome-wide expression patterns | Q24644463 | ||
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study | Q24651897 | ||
Statistics review 12: survival analysis | Q24800418 | ||
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. | Q27824849 | ||
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia | Q29614324 | ||
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia | Q33591867 | ||
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia | Q33680280 | ||
The logrank test | Q33685983 | ||
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia | Q33985127 | ||
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). | Q35616078 | ||
Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia | Q35750961 | ||
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. | Q36098242 | ||
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group | Q36478435 | ||
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study | Q36713493 | ||
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia | Q37172988 | ||
JAK mutations in high-risk childhood acute lymphoblastic leukemia | Q37224111 | ||
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected] | Q37331114 | ||
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia | Q37440638 | ||
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group | Q39766394 | ||
Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. | Q40556012 | ||
Racial and ethnic differences in survival of children with acute lymphoblastic leukemia | Q40637235 | ||
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia | Q40961746 | ||
Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study | Q46369449 | ||
COPA--cancer outlier profile analysis | Q51935849 | ||
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia | Q53307880 | ||
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias | Q53570084 | ||
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling | Q61910882 | ||
P433 | issue | 23 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | leukemia | Q29496 |
lymphoblastic leukemia | Q18553852 | ||
P304 | page(s) | 4874-4884 | |
P577 | publication date | 2010-08-10 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome | |
P478 | volume | 116 |
Q38726016 | A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration |
Q58690864 | Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia |
Q28306608 | Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target |
Q37517874 | Absence of Genomic Ikaros/IKZF1 Deletions in Pediatric B-Precursor Acute Lymphoblastic Leukemia |
Q42226188 | Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. |
Q58481753 | Acute lymphoblastic leukaemia |
Q91565663 | Acute lymphoblastic leukaemia |
Q58481759 | Acute lymphoblastic leukemia |
Q38502885 | Adolescent and young adult patients with cancer: a milieu of unique features |
Q61449792 | Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications |
Q36752634 | Advances in the Biology of Acute Lymphoblastic Leukemia—From Genomics to the Clinic |
Q38009099 | Advances in the molecular pathobiology of B-lymphoblastic leukemia |
Q35869978 | An advanced fragment analysis-based individualized subtype classification of pediatric acute lymphoblastic leukemia |
Q43922213 | An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. |
Q88091540 | An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression |
Q37146303 | Analysis of Patterns of Gene Expression Variation within and between Ethnic Populations in Pediatric B-ALL |
Q35835290 | Apoptosis pathway signature for prediction of treatment response and clinical outcome in childhood high risk B-Precursor acute lymphoblastic leukemia |
Q38944847 | Arf proteins in cancer cell migration. |
Q83860818 | Attacking Remaining Challenges in Childhood Leukemia |
Q36070046 | Aurora B Overexpression Causes Aneuploidy and p21Cip1 Repression during Tumor Development |
Q42371687 | B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy |
Q26798093 | B-acute lymphoblastic leukemia/lymphoblastic lymphoma |
Q38050656 | B-lineage transcription factors and cooperating gene lesions required for leukemia development |
Q90611076 | BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat? |
Q34033206 | BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia |
Q34755687 | Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia |
Q36717196 | Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma |
Q34207183 | Cancer gene prioritization by integrative analysis of mRNA expression and DNA copy number data: a comparative review |
Q38063923 | Cancer in Australian Aboriginal children: Room for improvement |
Q37331221 | Characterization of leukemias with ETV6-ABL1 fusion |
Q33777616 | Childhood B-acute lymphoblastic leukemia: a genetic update |
Q28080463 | Childhood acute lymphoblastic leukemia: Integrating genomics into therapy |
Q33711119 | Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia |
Q84948480 | Clinical and Laboratory Biology of Childhood Acute Lymphoblastic Leukemia |
Q92627035 | Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia |
Q36561755 | Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia |
Q36366616 | Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification |
Q47164848 | Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients |
Q36106034 | Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia |
Q27853385 | Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia |
Q89777602 | Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice |
Q35053686 | Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients |
Q59529214 | Cooperative genetic changes in pediatric B-cell precursor acute lymphoblastic leukemia with deletions or mutations ofIKZF1 |
Q64090852 | Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia |
Q48323019 | Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms |
Q39094566 | DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia. |
Q42068556 | Deciphering "B-others": Novel fusion genes driving B-cell acute lymphoblastic leukemia |
Q38757530 | Defective quorum sensing of acute lymphoblastic leukemic cells: evidence of collective behavior of leukemic populations as semi-autonomous aberrant ecosystems |
Q50860875 | Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. |
Q34273750 | Depletion of Cytotoxic T-Cells Does Not Protect NUP98-HOXD13 Mice from Myelodysplastic Syndrome but Reveals a Modest Tumor Immunosurveillance Effect |
Q37483972 | Deregulation of DUX4 and ERG in acute lymphoblastic leukemia |
Q47109080 | Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis |
Q52686108 | Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing |
Q26824387 | Diagnosis and subclassification of acute lymphoblastic leukemia |
Q39186808 | Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations |
Q33998291 | Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group |
Q52882383 | ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia |
Q37594153 | ETS-related gene is a novel prognostic factor in childhood acute lymphoblastic leukemia |
Q38844207 | ETV6/RUNX1-like acute lymphoblastic leukemia: A novel B-cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype. |
Q26770327 | Emerging technologies in paediatric leukaemia |
Q34790870 | Evaluation of a side population of canine lymphoma cells using Hoechst 33342 dye |
Q35079398 | Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia |
Q88104986 | Expression of Coagulation Factor XIII Subunit A Correlates with Outcome in Childhood Acute Lymphoblastic Leukemia |
Q64111281 | Feedforward regulation of Myc coordinates lineage-specific with housekeeping gene expression during B cell progenitor cell differentiation |
Q37500159 | Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia |
Q88160433 | GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer |
Q35802220 | Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study |
Q39180500 | Genetic Basis of Acute Lymphoblastic Leukemia |
Q36174146 | Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia |
Q38716760 | Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL. |
Q36778481 | Genetic risk prediction for normal-karyotype acute myeloid leukemia using whole-exome sequencing |
Q57175475 | Genetics and epigenetics of pediatric leukemia in the era of precision medicine |
Q37408629 | Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia |
Q41000106 | Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia |
Q38223490 | Genomic characterization of acute leukemias |
Q37359118 | Genomic characterization of childhood acute lymphoblastic leukemia |
Q91249010 | Global efforts toward the cure of childhood acute lymphoblastic leukaemia |
Q91522449 | H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells |
Q37580303 | High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement |
Q49692632 | High PDGFRA expression does not serve as an effective therapeutic target in ERG-deleted B-cell precursor acute lymphoblastic leukemia |
Q50043074 | High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia |
Q36765731 | High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia |
Q41823245 | High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. |
Q34645259 | High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? |
Q90466697 | How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia |
Q101226735 | IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells |
Q36862420 | IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol |
Q41688725 | IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951. |
Q36977450 | IKZF1 deletion is associated with a poor outcome in pediatric B‐cell precursor acute lymphoblastic leukemia in Japan |
Q39730823 | IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan |
Q36980511 | Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia |
Q40791978 | Identification of a novel susceptibility locus at 16q23.1 associated with childhood acute lymphoblastic leukemia in Han Chinese |
Q34957024 | Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. |
Q42831329 | Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philade |
Q36058255 | Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group |
Q35688742 | Improving access to novel agents for childhood leukemia |
Q35971733 | In Search of Targeted Therapies for Childhood Cancer |
Q92377690 | Inclusion of special populations in clinical research: important considerations and guidelines |
Q37226741 | Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. |
Q39369458 | Inferior outcomes for black children with high risk acute lymphoblastic leukemia and the impact of socioeconomic variables |
Q33688248 | Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse |
Q92441849 | Integrated genetic and epigenetic analysis revealed heterogeneity of acute lymphoblastic leukemia in Down syndrome |
Q28602517 | Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors |
Q37533656 | Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma |
Q30842603 | Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study |
Q33580638 | Integrative Analysis of MicroRNA-Mediated Gene Signatures and Pathways Modulating White Blood Cell Count in Childhood Acute Lymphoblastic Leukemia |
Q26991810 | Janus kinase deregulation in leukemia and lymphoma |
Q58125084 | Keeping PACE with Ph Positive to Ph-Like Detection in B-Lineage Acute Lymphoblastic Leukemia: A Practical and Cost Effective (PACE) Approach in a Resource Constrained Setting |
Q35220417 | Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group |
Q28274115 | LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors |
Q36014047 | Lentiviral Vector Induced Insertional Haploinsufficiency of Ebf1 Causes Murine Leukemia |
Q35838562 | Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development |
Q43248878 | LncRNAs downregulated in childhood acute lymphoblastic leukemia modulate apoptosis, cell migration, and DNA damage response |
Q36246434 | Long non-coding RNA HOTAIR regulates cyclin J via inhibition of microRNA-205 expression in bladder cancer |
Q35827910 | Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia |
Q41978213 | MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. |
Q41667201 | Metabolic gatekeeper function of B-lymphoid transcription factors |
Q36688035 | Molecular Analysis of Central Nervous System Disease Spectrum in Childhood Acute Lymphoblastic Leukemia. |
Q47370037 | Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia. |
Q36351111 | NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity |
Q26749177 | New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia |
Q38724079 | Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future |
Q33551348 | Novel mechanism of tumor suppression by polarity gene discs large 1 (DLG1) revealed in a murine model of pediatric B-ALL. |
Q90458184 | Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL |
Q37883008 | Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults |
Q35885293 | Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study |
Q34172033 | Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease |
Q42376333 | Overexpression of dominant-negative Ikaros 6 isoform is associated with resistance to TKIs in patients with Philadelphia chromosome positive acute lymphoblastic leukemia |
Q37917735 | Pathobiology of acute lymphoblastic leukemia |
Q36163029 | Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? |
Q39027852 | Ph-like acute lymphoblastic leukemia |
Q39128765 | Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults |
Q54989161 | Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. |
Q43431904 | Philadelphia chromosome-like acute lymphoblastic leukemia |
Q45970621 | Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia. |
Q37166872 | Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group |
Q38117685 | Predicting relapse risk in childhood acute lymphoblastic leukaemia |
Q89777332 | Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways |
Q39992854 | Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes |
Q54120651 | Prognostic significance of copy number alterations detected by multi-link probe amplification of multiple genes in adult acute lymphoblastic leukemia |
Q53831155 | Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. |
Q92382762 | Prognostic significance of the tumor suppressor protein p53 gene in childhood acute lymphoblastic leukemia |
Q37673367 | Prognostic stratification improvement by integrating ID1/ID3/IGJ gene expression signature and immunophenotypic profile in adult patients with B-ALL. |
Q28087446 | Prognostification of ALL by Cytogenetics |
Q34381851 | Protein phosphatase 1 (PP1) and Casein Kinase II (CK2) regulate Ikaros-mediated repression of TdT in thymocytes and T-cell leukemia |
Q36265485 | RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia |
Q36713389 | RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction |
Q91287120 | Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905 |
Q52575378 | Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. |
Q92508206 | Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia |
Q35723998 | Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia |
Q64979087 | Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. |
Q26864460 | Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine |
Q90074518 | Regulation of Small GTPase Rab20 by Ikaros in B-Cell Acute Lymphoblastic Leukemia |
Q90638583 | Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols |
Q35106844 | Remaining challenges in childhood cancer and newer targeted therapeutics |
Q38264774 | Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention |
Q55057300 | Routine application of a novel MLPA-based first-line screening test uncovers clinically relevant copy number aberrations in haematological malignancies undetectable by conventional cytogenetics. |
Q36201677 | Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia |
Q91632856 | Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature |
Q38804856 | Signaling proteins and transcription factors in normal and malignant early B cell development. |
Q48681218 | Simultaneous use of multiplex ligation-dependent probe amplification assay and flow cytometric DNA ploidy analysis in patients with acute leukemia |
Q34325528 | Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. |
Q36323903 | Specific expression of novel long non-coding RNAs in high-hyperdiploid childhood acute lymphoblastic leukemia |
Q41228748 | Spontaneous loss of B lineage transcription factors leads to pre-B leukemia in Ebf1+/-Bcl-xLTg mice |
Q54966011 | Structural basis of DUX4/IGH-driven transactivation. |
Q82714412 | Taking childhood leukemia personally |
Q46711660 | Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group |
Q37438996 | Targeting High Dynamin-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia |
Q36352535 | Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia |
Q89723083 | Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients |
Q36128393 | The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia |
Q34235906 | The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia |
Q34167952 | The Origin and Nature of Tightly Clustered BTG1 Deletions in Precursor B-Cell Acute Lymphoblastic Leukemia Support a Model of Multiclonal Evolution |
Q95277349 | The Role of ARF Family Proteins and Their Regulators and Effectors in Cancer Progression: A Therapeutic Perspective |
Q37995811 | The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia |
Q57158107 | The genetic basis and cell of origin of mixed phenotype acute leukaemia |
Q48090552 | The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. |
Q41331438 | The non-coding RNA landscape of human hematopoiesis and leukemia. |
Q38508845 | The role of CCN family genes in haematological malignancies. |
Q36475964 | The role of phenotype in gene discovery in the whole genome sequencing era |
Q33700016 | The two main forms of histiocytic sarcoma in the predisposed Flatcoated retriever dog display variation in gene expression |
Q59810097 | Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia |
Q41090525 | Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia |
Q34182738 | Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase |
Q36571783 | Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia |
Q37967302 | Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Anemia |
Q36542815 | Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project |
Q34820332 | Unique Characteristics of Adolescent and Young Adult Acute Lymphoblastic Leukemia, Breast Cancer, and Colon Cancer |
Q32182056 | Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. |
Q28390558 | Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia |
Q90029220 | Using genomics to define pediatric blood cancers and inform practice |
Q33705933 | VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. |
Q90989897 | Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting |
Q26770729 | ZNF423 and ZNF521: EBF1 Antagonists of Potential Relevance in B-Lymphoid Malignancies |
Q58122394 | [The expression of CRLF2 in adult Ph negative acute B lymphocytic leukemia and its prognostic significance] |
Q35009302 | miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. |
Search more.